Floatz logo

T-Dxd

Additional Indications Below for Module 4 and 5

AstraZenecaantibody_drug_conjugatePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Additional Indications Below for Module 4 and 5 cohort.

Asset / SponsorPhaseRating
Carboplatin
AstraZeneca
Phase 1/2CCC
Camizestrant
AstraZeneca
Phase 1/2CCC
Datopotamab Deruxtecan
AstraZeneca
Phase 1/2CCC
azd5305
AstraZeneca
Phase 1/2CCC

Same molecule, other indications

T-Dxd is also rated in:

HER2 positive breast carcinomaDormant
B
Indicative ·
63 / 100
View asset →
Breast NeoplasmsDormant
B
Indicative ·
56 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →